Deerfield Management Company, L.P. (Series C) Ventyx Biosciences, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.04 Billion
- Q4 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 534,737 shares of VTYX stock, worth $812,800. This represents 0.03% of its overall portfolio holdings.
Number of Shares
534,737
Previous 6,715,501
92.04%
Holding current value
$812,800
Previous $14.6 Million
92.0%
% of portfolio
0.03%
Previous 0.27%
Shares
5 transactions
Others Institutions Holding VTYX
# of Institutions
134Shares Held
55.2MCall Options Held
81.4KPut Options Held
148K-
Black Rock Inc. New York, NY4.77MShares$7.25 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.48MShares$6.81 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC4.27MShares$6.5 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY4.05MShares$6.15 Million3.31% of portfolio
-
Ubs Group Ag3.78MShares$5.75 Million0.0% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $85.9M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...